Please wait a minute...

中国生物工程杂志

China Biotechnology
China Biotechnology  2013, Vol. 33 Issue (1): 8-13    DOI:
    
Expression of Enterovirus 71 VLP in Baculovirus System and Evaluation of Its Immunogenicity
GUO Li-li, OU Xia, MI Kai, SUN Mao-sheng, LI Hong-jun
Yunnan Engineering Center of Vaccine Research Development on Severe Infecticus Diseases Yunnan Keylaboratory of Vaccine Research & Development on Severe Infections Diseases, Kunming 650118, China
Download: HTML   PDF(1030KB) HTML
Export: BibTeX | EndNote (RIS)      

Abstract  Enterovirus type (EV71) is an etiologic agent responsible for seasonal epidemics of hand-foot-and-mouth disease and causes outbreaks with significant mortality among young children. Expression of enterovirus EV71 Virus-like Particles(VLP) in Bac-to-Bac Baculovirus Expression System and evaluated its immunogenicity. Recombinant AcMNPV-P1-3CD was obtained by transfecting the Bacmid-P1-3CD into the insect cell line of Sf9. The expressed protein was analyzed by IFA, Western blot methods and electron microscope obseruation, The VLPs of EV71 were observed by Electron microscope, while its immunogenicity was measured by ELISA and Microneutralization. The result reveals that EV71 VLP expressed by Recombinant AcMNPV-P1-3CD has strong immunogenicity, which is helpful for the development of the vaccine against EV71 infection.

Key wordsHFMD      EV71      VLP      Bac-to-bac expression system      Immunogenicity     
Received: 25 October 2012      Published: 25 January 2013
ZTFLH:  Q527  
Cite this article:

GUO Li-li, OU Xia, MI Kai, SUN Mao-sheng, LI Hong-jun. Expression of Enterovirus 71 VLP in Baculovirus System and Evaluation of Its Immunogenicity. China Biotechnology, 2013, 33(1): 8-13.

URL:

https://manu60.magtech.com.cn/biotech/     OR     https://manu60.magtech.com.cn/biotech/Y2013/V33/I1/8

[1] 陈伟雄.手足口病的最新研究进展及预防措施. 社区医学杂志, 2011,9 (19):10-12. Chen W X. Research advances and prevention measures of hand-foot-mouth disense. JCM, 2011, 9(19):10-12.
[2] Ooi M H, Solomon T, Podin Y, et al. Evaluation of different clinical sample types in diagnosis of human enterovirus 71-associated hand-foot-and-mouth disease. Journal of Clinical Microbiology, 2007, 45: 1858-1866.
[3] Huang C C, Liu C C, Chang Y C, et al. Neurologic complications in children with enterovirus 71 infection.The New England Journal of Medicine, 1999, 341: 936-942.
[4] Cardosa M J, Perera D, Brown B A, et al. Molecular epidemiology of human enterovirus 71 strains and recent outbreaks in the Asia-Pacific region: comparative analysis of the VP1 and VP4 genes. Emerg Infect Dis, 2003, 9:461-468.
[5] Yang F, Ren L, Xiong X, et al. Enterovirus 71 outbreak in the people’s republic of china in 2008. J Clin Microbiol, 2009, 47: 2351-2352.
[6] 陈宏, 苏俐. 手足口病的研究现状. 现代中西医结合杂志, 2012, 21(2):224-226. Chen X, Su L. Research advances of hand-foot-macth disease. Modern Journal of Integrated Traditional Chinese and Western Medicine, 2012, 21(2):224-226.
[7] Li R Q, Chen L J, Wang Y M, et al. Genetic characteristics of enterovirus 71 isolated in Beijing, 2006-2008. Chin J Epidemiol, 2009, 30(1):45-49.
[8] Chung Y C, Ho M S, Wu J C, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine, 2008, 26(15):1855-1862
[9] 郝翊, 秦川. 人肠道病毒71型亚单位疫苗的研制. 中国比较医学杂志, 2010, 20(6): 7-12. Hao Y, Qin C. Preporation of Subcenit vaccine for human enterovirus 71. Chinese Journal of Comparative Medicine, 2010, 20 (6):7-12.
[10] Dingmei Zhang, Jiayuan Lu, Jiahai Lu. Enterovirus 71 vaccine: close but still far. International Journal of Infections Diseases, 2010, 14: 739-747.
[11] Mcminn P C. An overview of the evolution of enterovirus 71 and its clinical and public health significance. FEMS Microbiol Rev, 2002;26(1):91-107.
[12] Brown B A, Oberste M S, Alexander Jr Jp, et al. Molecular epidemiology and evolution of enterovirus 71 strains isolated from 1970 to 1998. J Virol, 1999, 73(12):9969-9975.
[13] 曹蕾, 伊瑶, 宋敬东等. 杆状病毒表达EV71病毒颗粒的装配、制备纯化与鉴定. 病毒学报, 2012, 28(3):201-206. Cao L, Yi Y, Song J D, et al. The assuemblage, purification and cheracterization of EV71VIPs expressed in Baculovirus. Chinese Journal of Virology, 2012, 28(3): 201-206.
[14] Foo D G, Alonso S, Chow V T, et al. Passive protection against lethal enterovirus 71 infection in newborn mice by neutralizing antibodies elicited by a synthetic peptide. Microbes Infect, 2007;9:1299-306.
[15] Chung Y C, Huang J H, Lai C W, et al. Expression, purification and characterization of enterovirus-71 virus-like particles. World J Gastroenterol, 2006, 12(6):921-927.
[16] 刘拂晓, 柳增善, 王志亮. 杆状病毒表达系统-有效的VLP构建工具. 生物技术通报, 2012:6:25-31. Liu F X, Liu Z S, Wang Z L. Baculevirus expression system-effective tool of VLP procluotion. Biotechnology Bulletin, 2012:6:25-31.
[17] 黄任和, 余模松. 测定杆状病毒滴度方法的研究进展. 微生物学免疫学进展, 2007, 35(2):79-83. Huang S H, Yu M S. Research advence of the determiration method for the titer of the baculovirus. Prog in Microbiol Immunol, 2007, 35 (2):79-83.
[18] Yao-Chi Chung, Mei-Shang Ho, Yu-Chen Hu, et al. Immunization with virus-like particles of enterovirus 71 elicits potent immune responses and protects mice against lethal challenge. Vaccine, 2008, 26:1855-1862.
[19] Yu-Li Lin, Chun-I Yu, Yu-Chen Hu, et al. Enterovirus type 71 neutralizing antibodies in the serum of macaque monkeys immunized with EV71 virus-like particles. Vaccine, 2012, 30:1305-1312.
[1] JIANG Dan-dan,WANG Yun-long,LI Yu-lin,Zhang Yi-qing. Study on the Delivery of RGD Modified Virus-Like Particles to ICG Targeted Tumors[J]. China Biotechnology, 2020, 40(7): 22-29.
[2] XIE Hang-hang,BAI Hong-mei,YE Chao,CHEN Yong-jun,YUAN Ming-cui,MA Yan-bing. The Purification Procedure for the Recombinant HBcAg Virus-like Particle Easy to Generate Aggregation[J]. China Biotechnology, 2020, 40(5): 40-47.
[3] CEN Qian-hong,GAO Tong,REN Yi,LEI Han. Recombinant Saccharomyces cerevisiae Expressing Helicobacter pylori VacA Protein and Its Immunogenicity Analysis[J]. China Biotechnology, 2020, 40(5): 15-21.
[4] QI Jia-long, GAO Rui-yu, JIN Shu-mei, GAO Fu-lan, YANG Xu, MA Yan-bing, LIU Cun-bao. Expression and Identification of Varicella-Zoster Virus Glycoprotein E and Immunogenicity Assay[J]. China Biotechnology, 2019, 39(8): 17-24.
[5] Lei-zhao HUA,Xiao-ping YI,Ju CHU,Ying-ping ZHUANG,Si-liang ZHANG. Process Control and Optimization of PCV2 Production of VLPs Based on PAT[J]. China Biotechnology, 2018, 38(8): 50-58.
[6] Li DU,Xiao-zhi LIU,Jian GAO,Zhi-ming WANG. Research Progress on Immunogenicity Evaluation of Antibodies[J]. China Biotechnology, 2018, 38(2): 89-94.
[7] SUN Wen-jia, YAO Yu-feng, YANG Xu, HUANG Wei-wei, LIU Cun-bao, LONG Qiong, CHU Xiao-jie, MA Yan-bing. Presentation of HPV 16L1 Peptide-based HBcAg Virus-like Particle and Induction of Specific Antibody[J]. China Biotechnology, 2017, 37(3): 58-64.
[8] Jian-rong WU,Xing-qiao PENG,Xiao-bei ZHAN. Advance in Application of Polysialic Acid,a Non-GAGs, Non-immunogenic Biomaterial[J]. China Biotechnology, 2017, 37(12): 96-102.
[9] WANG Jing, XIA Wen-yue, PAN Xiao-xia, ZHAO Bing-xin, TENG Yu-mei, LI Chuan-yin, YANG Xiao-zhou, WEN Yu-ling, CHEN Yuan-ding. Immunological Activity of a Chimeric Protein Carrying an Epitope of Type 2 Poliovirus on the VP6 of Rotavirus as a Vector[J]. China Biotechnology, 2016, 36(8): 1-8.
[10] LIU Pan-rao, ZHOU Xue-chen, ZHU Xue-jiao, BAI Juan, WANG Xian-wei, JIANG Ping. The Soluble Expression of Porcine Circovirus Type 2 Cap Gene in Escherichia coli and Its Immunogenicity in Mice[J]. China Biotechnology, 2016, 36(4): 50-56.
[11] ZHANG Xu-fan, HU Fa-biao, MA Xing-yuan, WANG Tian-wen, WANG Ping, WANG Xiao-li. Design, Construction, Characterization and Preliminary Activity Research of Universal Influenza Virus Vaccine(Flu@uV) Delivered by Hepatitis B Virus Core Protein(HBc-VLP)[J]. China Biotechnology, 2016, 36(2): 7-15.
[12] SUN Peng-yan, LI Kui, LIU Cun-bao, YAO Yu-feng, CHU Xiao-jie, BAI Hong-mei, YANG Xu, HUANG Wei-wei, SUN Wen-jia, MA Yan-bing. Co-expression of Ebola Virus GP and VP40 Proteins and Virus-like particles Assembly in Mammalian Cells[J]. China Biotechnology, 2016, 36(12): 66-71.
[13] CHU Xiao-jie, LI Yang, LONG Qiong, YAO Yu-feng, SUN Wen-jia, HUANG Wei-wei, YANG Xu, Liu Cun-bao, MA Yan-bing. Development of a HPV16 E7 CTLs Peptides-based Virus-like Particle Therapeutic Vaccine[J]. China Biotechnology, 2015, 35(2): 45-51.
[14] LI Duo, YANG LI-juan, ZHAO Yu-jiao, PAN Yue, CHEN Jun-ying, FU Juan-juan, HUANG Xing-wei, QUE Li-juan, SUN Qiang-ming. Clone, Expression and Immunological Analysis of Type Ⅱ Dengue Virus NS1 Protein[J]. China Biotechnology, 2014, 34(9): 4-8.
[15] JIANG Bo, BI Yan-wei, ZHANG Ying-ying, CAI Lu-kui, JI Qiu-yan, LI Zhi-hua, XU Wei-ming. Prokaryotic Expression and Immunogenicity Analysis of HPV16 L2 Peptide Coupled to AP205VLP[J]. China Biotechnology, 2012, 32(6): 1-6.